ArriVent BioPharma (AVBP) Stock News

ArriVent BioPharma (AVBP) resumed trading after a halt for pending news and plunged 52.61% to $13.49. The stock is on track for a new all-time closing low and the largest percent decrease on record. Intraday low was $11.36. No reason has been given for the move.

ArriVent BioPharma said firmonertinib monotherapy did not show meaningful improvement in progression-free survival over chemotherapy in a Phase 3 trial for previously untreated non-squamous non-small cell lung cancer. Shares fell 59% to $11.77 in premarket trading. CEO Bing Yao said the company is reviewing the full dataset to determine the drug's development path.

ArriVent BioPharma Inc. (AVBP) has resumed trading on the exchange after being halted earlier today pending news. The company has not disclosed the nature of the news that prompted the halt.

ArriVent BioPharma said it is evaluating the full FURVENT dataset to determine the most appropriate development path for firmonertinib. The statement follows a trading halt. No results or decisions were disclosed.

ArriVent BioPharma (AVBP) announced that its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC did not meet the primary endpoint of progression-free survival by BICR. Clinical benefit was observed in secondary endpoints. The stock was halted pending the news.

ArriVent BioPharma (AVBP) reported a trend toward improvement in overall survival in its clinical data, though the data are not yet mature. This follows earlier reports of clinical benefit in secondary endpoints including progression-free survival and objective response rate.

No new safety signals identified in the FURVENT study. The safety profile was consistent with previous clinical studies of firmonertinib.

ArriVent BioPharma said its clinical trial did not meet the primary endpoint of progression-free survival by blinded independent central review. The company described the results as disappointing. A trend toward improvement in overall survival was observed but is not yet mature.